Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan
Status:
Completed
Trial end date:
2000-09-01
Target enrollment:
Participant gender:
Summary
To determine the tolerability and efficacy of eletriptan in patients who had discontinued
oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous
clinical treatment (not a controlled trial).
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.